Vijay N. Yewale
Vijay N. Yewale has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Abhishek Kunwar
Ministry of Health & Family Welfare, Government of India, New Delhi, India
2 shared publications - Arun Katkar
Ministry of Health & Family Welfare, Government of India, New Delhi, India
2 shared publications - Chenhua Zhang
Global Immunization Division, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia
2 shared publications - Christopher LeBoa
Department of Environmental Health Sciences, University of California, Berkeley 2121 Berkeley Way West, Berkeley, CA 94720-3114, United States
2 shared publications - Debjit Chakraborty
National Institute of Cholera and Enteric Diseases, Indian Council of Medical Research, Kolkata, India
2 shared publications Dhanya Dharmapalan
General Pediatric Division, Dr. Yewale's Multispeciality Hospital for Children, Vashi, Navi Mumbai 400703, India
2 shared publications
Latest Publications
- Open Access
- 6 November 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (5) , 1060-1065
Factors Influencing Vaccine Receipt During a 2018 Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India
: In 2018, the Navi Mumbai Municipal Corporation implemented phase 1 of a public sector typhoid conjugate vaccine campaign in Navi Mumbai, India, targeting all children aged 9 months to 14 years within its administrative boundaries. To assess associations with receipt of vaccine in phase 1, we used generalized estimating equations to calculate estimates of vaccination by child-, household-, and community-level demographics (child education and age; household head education, income, and occupation; community informal settlement percent). Campaign vaccine receipt was most associated with children enrolled in school (odds ratio [OR] = 3.84, 95% CI: 2.18–6.77), the lowest household income tertile when divided into three equal parts (OR = 1.64, 95% CI: 1.43–1.84), and lower community-level socioeconomic status (OR = 1.06, 95% CI: 1.04–1.08 per 10% informal settlement proportion). The campaign was successful in reaching the most underserved populations of its target communities.
- 6 November 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (5) , 1060-1065
Open AccessFactors Influencing Vaccine Receipt During a 2018 Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India
: In 2018, the Navi Mumbai Municipal Corporation implemented phase 1 of a public sector typhoid conjugate vaccine campaign in Navi Mumbai, India, targeting all children aged 9 months to 14 years within its administrative boundaries. To assess associations with receipt of vaccine in phase 1, we used generalized estimating equations to calculate estimates of vaccination by child-, household-, and community-level demographics (child education and age; household head education, income, and occupation; community informal settlement percent). Campaign vaccine receipt was most associated with children enrolled in school (odds ratio [OR] = 3.84, 95% CI: 2.18–6.77), the lowest household income tertile when divided into three equal parts (OR = 1.64, 95% CI: 1.43–1.84), and lower community-level socioeconomic status (OR = 1.06, 95% CI: 1.04–1.08 per 10% informal settlement proportion). The campaign was successful in reaching the most underserved populations of its target communities.
- Open Access
- 13 August 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (4) , 848-852
Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign
Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05–0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0–95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.
- 13 August 2024
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 111 (4) , 848-852
Open AccessField Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign
Typbar-TCV®, a typhoid conjugate vaccine (TCV), was prequalified by the World Health Organization in 2017. We evaluated its effectiveness in a mass vaccination program targeting children 9 months to 14 years in Navi Mumbai, India, from September 2018 to July 2020. We compared laboratory-confirmed typhoid cases from six clinical sites with age-matched community controls. Of 38 cases, three (8.6%) received TCV through the campaign, compared with 53 (37%) of 140 controls. The adjusted odds ratio of typhoid fever among vaccinated children was 0.16 (95% CI: 0.05–0.55), equivalent to a vaccine effectiveness of 83.7% (95% CI: 45.0–95.3). Vaccine effectiveness of Typbar-TCV in this large public sector vaccine introduction was similar to prior randomized controlled trials, providing reassurance to policymakers that TCV effectiveness is robust in a large-scale implementation.
- Open Access
- 1 March 2024
- Published by Mansa STM Publishers in Indian Journal of Child Health
- Vol. 10 (12) , 145-150
Inactivated TZ84 strain hepatitis A vaccine and its impact: A narrative review
Hepatitis A (HepA) represents a significant global public health challenge. At present, there is no definitive treatment available for managing HepA. Before the availability of HepA vaccines, hepatitis A virus (HAV) infection had emerged as a leading cause of fulminant hepatic failure and a significant indication for liver transplantation in children living in Argentina, Brazil, the Republic of Korea, and India. Inactivated HAV vaccines have demonstrated a high level of immunogenicity. In addition, there is evidence supporting the use of inactivated HepA vaccines in immunocompromised individuals and as post-exposure prophylaxis. Recently, the inactivated TZ84 strain hepatitis A vaccine, which has shown superior immunogenicity for up to 30 years and fewer adverse reactions when compared with other inactivated HepA vaccines, has become available in India. Moreover, the TZ84 strain of the inactivated HAV vaccine has the potential to control community-wide outbreaks. This narrative review offers an overview of the existing evidence concerning immunization against HepA in India, with a particular emphasis on the TZ84 strain of the inactivated HAV vaccine.
- 1 March 2024
- Published by Mansa STM Publishers in Indian Journal of Child Health
- Vol. 10 (12) , 145-150
Open AccessInactivated TZ84 strain hepatitis A vaccine and its impact: A narrative review
Hepatitis A (HepA) represents a significant global public health challenge. At present, there is no definitive treatment available for managing HepA. Before the availability of HepA vaccines, hepatitis A virus (HAV) infection had emerged as a leading cause of fulminant hepatic failure and a significant indication for liver transplantation in children living in Argentina, Brazil, the Republic of Korea, and India. Inactivated HAV vaccines have demonstrated a high level of immunogenicity. In addition, there is evidence supporting the use of inactivated HepA vaccines in immunocompromised individuals and as post-exposure prophylaxis. Recently, the inactivated TZ84 strain hepatitis A vaccine, which has shown superior immunogenicity for up to 30 years and fewer adverse reactions when compared with other inactivated HepA vaccines, has become available in India. Moreover, the TZ84 strain of the inactivated HAV vaccine has the potential to control community-wide outbreaks. This narrative review offers an overview of the existing evidence concerning immunization against HepA in India, with a particular emphasis on the TZ84 strain of the inactivated HAV vaccine.
- 1 December 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (12) , 957-958
‘Two birds, one stone’ approach — Integrated action plan for pneumonia and diarrhea
- 1 December 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (12) , 957-958
‘Two birds, one stone’ approach — Integrated action plan for pneumonia and diarrhea
- Open Access
- 1 November 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (11) , 861
Indian Academy of Pediatrics — Integral part of India Newborn Action Plan
- 1 November 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (11) , 861
Open AccessIndian Academy of Pediatrics — Integral part of India Newborn Action Plan
- Open Access
- 1 October 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (10) , 773
Mission : Avoid antibiotic abuse
- 1 October 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (10) , 773
Open AccessMission : Avoid antibiotic abuse
- 19 September 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (9) , 691
Government of India’s boost to Country’s immunization
- 19 September 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (9) , 691
Government of India’s boost to Country’s immunization
- 28 August 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (8) , 605-606
Misery of mystery of Muzaffarpur
- 28 August 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (8) , 605-606
Misery of mystery of Muzaffarpur
- 1 June 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (6) , 437-439
IAP-ICMR call to action to tackle the antimicrobial resistance
- 1 June 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (6) , 437-439
IAP-ICMR call to action to tackle the antimicrobial resistance
- Open Access
- 14 May 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (5) , 347-348
“Out of the dangerous wild, but not yet out of woods” — The polio end game strategy
- 14 May 2014
- Published by Springer Nature in Indian Pediatrics
- Vol. 51 (5) , 347-348
Open Access“Out of the dangerous wild, but not yet out of woods” — The polio end game strategy